Who we are
Building on the positive momentum from MAPS’ phase 3 RCT on MDMA-assisted therapy for PTSD, which showed significant reductions in eating disorder risk, in addition to real-world pilot data demonstrating that MDMA-assisted IFS therapy significantly improved eating disorder symptoms, we are excited to be launching the world’s first study on MDMA-assisted IFS therapy for anorexia nervosa in young adults in 2027.
The MAYA study is anticipated to enroll approximately 30 participants.
Our goal is to empower young people with anorexia to become their own healers — restoring self-trust, fostering healthy development, and enabling lasting recovery.
Contact us
Interested in working together? Fill out some info and we will be in touch shortly. We can’t wait to hear from you!